![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Chabot Isabelle Rocchi Angela
Publisher: Blackwell Publishing
ISSN: 1098-3015
Source: Value in Health, Vol.13, Iss.6, 2010-09, pp. : 837-845
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Ravasio Roberto Ortega Cinzia Sabbatini Roberto Porta Camillo
Clinical Drug Investigation, Vol. 31, Iss. 7, 2011-07 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Johnston Karissa M. Marra Carlo A. Connors Joseph M. Najafzadeh Mehdi Sehn Laurie Peacock Stuart J.
Value in Health, Vol. 13, Iss. 6, 2010-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
First-line sunitinib cost-effective alternative to interferon-α in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Ray Joshua A. Carr Emma Lewis Gavin Marcus Robert
Value in Health, Vol. 13, Iss. 4, 2010-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sunitinib malate for the treatment of renal cell carcinoma
By Wood Lori
Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 9, 2012-06 ,pp. :